News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Non Addictive pain management is worth Billion's. We could be sitting on a gold mine here.
The fact that the one debt holder restructured his notes for a year out tells me that he knows something big is coming! Again very glad to have built a nice position here, because on the right announcement we will be hitting multi pennies.
One Material Event👍️
Complete and total Patience here!
One day, even 1 hour can make the difference. I have witnessed it many times! Sometimes on the wrong side of the trade and missing out. Ugh. Not here. Good to be on board!
Word is starting to spread and people don't want to be without shares. One major press release of a partnership and we will be looking at multi-pennies. I am glad I built my position here!
OTCN was the only MM on the ask and now .0012s up and hit..THIN!!!
We as investors can send out the message to other Bio boards in an attempt to find Bio backgrounds that can shed some perspective on this. I've been in ENZ? and it appears that these individuals are taking forever to get some of these things done while this company moves 10 times as fast. They also communicate better than that other Bio company. This company appears to have a drive to achieve their vision as well as keep their shareholders up to date on that progress.
We need someone with a Bio background that understands the application and testing process to take over the DD on this company. That info is the ticket to getting out ahead of all the other investors. I think this company is close to breaking out due to their results and where they are with so many potential drug candidates. The company appears to have their shit together in the way they continue to push ahead and continue to get positive results in much needed markets focusing on severe illnesses.
I agree....0011s up now though.Lets finish with an uptick!
I would just like to address the question that was just asked of posters on this board. Maybe the posters already own shares and don't artificially inflate the price of the stock by buying limited shares at a higher price. to pump the stock. We express positive opinions on newly releases test results that show the true potential of this company and it's IP and drugs that are actively being tested in the pipeline. A pumper would make up over the top claims about the company and its products to attempt to flip the stock. That doesn't appear to be the case here. Just curious. How many shares are owned by individuals who ask these types of questions or make ridicules statements. It appears the posters interest here is for success of the company and its pipeline of drugs. I'm sure you are here for the same reason! Good Luck and welcome to the ignore list !
Sooner than Later
The company has continued its relationship with Ponto Ventures LLC/Mr. Clodfelter and I believe if they weren't making progress they would not continue to do so. My belief is Resolution RX is well underway. Mr Clodfelter is paid shares based on .0015 PPS and has many incentives to bring forth investment dollars, sale, or partnership.
We see recently see a focus on the other drugs in their pipeline. I think this is a very positive sign. There is so much value here.
Mr. Clodfelter is well positioned to make some incredible progress and he has skin in this game with the shares he has earned and also has incredible incentive with the sharing in some form the fruits of the positive relationships he can bring to $RSPI.
This is not a long time wait imho.
The more I look into this company and hear about their progress. The more excited I get about the legitimacy of the company and their products. If I get that impression then imagine what BP may be thinking about this company. This is definitely a sleeping giant.
Will be interesting to see if in the near future the company discloses any talks they may have with BP interested in partnering with one of the potential drugs or asking to license the drug for manufacturing .
The PR Reflects Again the Strength of Their Pipeline👍️
None of us know when this is going to lift-off. I do not recall of any pharma I have been in that has the VAST Diverse Pipeline
of potential $RSPI has!
Glad to be Here!👍️
I cant believe all the amazing positive news that this company has gotten in under 10 days. This is looking like a extremely bright future for a solid investment. Multiple drugs making excellent positive progress in areas of great need. Should be nice to start to see this legit company get the attention they deserve and have sop far earned.
|
Followers
|
349
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
52305
|
|
Created
|
12/30/04
|
Type
|
Free
|
| Moderators DTGoody crazy horse 0 Lime Time archilles jacksonjohn | |||
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
| Form Type | Received | Period End Date | Report |
|---|---|---|---|
| 8-K | 09/06/2024 | 08/30/2024 | PDFRTFHTMLXLS |
| 8-K | 08/02/2024 | 07/29/2024 | PDFRTFHTMLXLS |
| 8-K | 07/08/2024 | 07/02/2024 | PDFRTFHTMLXLS |
| 8-K | 05/29/2024 | 05/29/2024 | PDFRTFHTMLXLS |
| 8-K | 04/16/2024 | 04/10/2024 | PDFRTFHTMLXLS |
| NT 10-K | 04/01/2024 | 12/31/2023 | PDFRTFHTMLXLS |
| 8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
| 8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
| 8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
| 10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
AI
